Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer;Wirkmechanismen der intravesikalen BCG-immuntherapie des oberflächlichen harnblasenkarzinoms

Urologe - Ausgabe A

Volumn 45, Issue 5, 2006, Pages 629-636

  Bohle A ^a   Suttmann, H ^b   Brandau, S ^c  

^a HELIOS AGNES KARLL HOSPITAL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Bacille Calmette Gu rin (BCG); Bladder cancer; Immunotherapy

Indexed keywords

BCG VACCINE;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RISK; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; IMMUNOSTIMULATION; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CANCER VACCINES; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33646878113     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-006-1059-x     Document Type: Review

References (68)

1. Arnold J, de Boer EC, O'Donnell MA et al. (2004) Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J Immunother 27: 116-123
2. Behr MA, Wilson MA, Gill WP et al. (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284: 1520-1523
3. Böhle A, Gerdes J, Ulmer AJ et al. (1990) Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53-58
4. Böhle A, Busemann E, Gerdes J et al. (1990) Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 144: 59-64
5. Brandau S, Suttmann H, Riemensberger J et al. (2000) Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res 6: 3729-3738
6. Brandau S, Riemensberger J, Böhle A et al. (2001) NK cells are essential for effective BCG immunotherapy. Int J Cancer 92: 697-702
7. Brandau S, Bohle A (2001) Activation of natural killer cells by Bacillus Calmette-Guerin. Eur Urol 39: 518-524
8. Chapman PB, Houghton AN (1993) Non-antibody immunotherapy of cancer. Curr Opin Immunol 5: 726-731
9. ChenX, LuoY, YamadaH, O'Donnell MA (2001) BCG potentiates human chemokine induction in vivo and in vitro. J Urol A 165: 465
10. Chin JL, Kadhim SA, Batislam E et al. (1996) Mycobacterium cell wall: an alternative to intravesical Bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol 156: 1189-1193
11. Clinton SK, Canto E, O'Donnell MA (2000) Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin North Am 27: 147-155
12. de Boer EC, de Jong WH, van der Meijden AP et al. (1991) Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 19: 45-50
13. de Boer EC (1992) Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother 34: 306-312
14. de Boer EC (1997) Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res 25: 31-34
15. de Reijke TM Vos PCN, de Boer EC et al. (1993) Cytokine production by the human bladder carcinoma cell line T24 in the presence of Bacillus Calmette-Guérin. Urol Res 21: 349-352
16. Esuvaranathan K (1995) Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol 154: 572-575
17. Gunther JH, Jurczok A, Wulf T et al. (1999) Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 59: 2834-2837
18. Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136: 970-974
19. Hawkyard SJ, Jackson AM, James K et al. (2005) The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol 147: 1399-1403
20. Herr HW ,Schwalb DM, Zhang ZF et al. (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13: 1404-1408
21. Jackson AM, Alexandroff AB, McIntyre M et al. (1994) Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol 47: 309-312
22. Jackson AM, Prescott S, Hawkyard SJ et al. (1995) Changes in urinary cytokines and soluble inter-cellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99: 369-375
23. Jackson AM (1998) Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J Urol 159: 1054-1063
24. Kaempfer R (1996) Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 14: 1778-1786
25. Kavoussi LR, Brown EJ, Ritchey, JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85: 62-67
26. Kelley DR, Haaff EO, Becich M et al. (1985) Intravesical bacillus Calmette-Guérin-therapy for superficial bladder cancer: Effect of bacillus Calmette-Guérin viability on treatment results. J Urol 134: 48-53
27. Lage JM, Bauer WC, Kelley DR et al. (1986) Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer. J Urol 135: 916-919
28. Lamm DL ,Crawford ED, Blumenstein BA et al.(1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205-1209
29. Lamm DL (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124-1129
30. Ludwig AT (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64: 3386-3390
31. Luo Y, Chen X, Downs T et al. (1999) IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 162: 2399-2405
32. Luo Y, Chen X, Han R, O'Donnell MA (2001) Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123: 264-270
33. Luo Y (2004) Recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 137: 24-34
34. Mahairas GG, Sabo PJ, Hickey MJ et al. (1996) Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 178: 1274-1282
35. Malmstrom PU, Wijkstrom H, Lundholm C et al. (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161: 1124-1127
36. McAveney KM, Gomella LG, Lattime EC (1994) Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother 39: 401-406
37. Mendez-Samperio P, Ayala-Verdin HE, Trejo-Echeverria A (1999) Interleukin-12 regulates the production of Bacille Calmette-Guerin-induced interferon-gamma from human cells in a CD40-dependent manner. Scand J Immunol 50: 61-67
38. Mizutani Y, Nio Y, Fukumoto M, Yoshida O (1992) Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer 69: 537-545
39. Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116: 180-183
40. Morales A, Chin JL, Ramsey EW (2001) Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 166: 1633-1638
41. O'Donnell MA, Arnold J, de Boer EC et al. (1999) Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. J Immunol 163: 4246-4252
42. O'Donnell MA, Lilli K, Leopold C (2004) Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172: 888-893
43. Poppas DP, Pavlovich CP, Folkman J et al. (1998) Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 52: 268-275
44. Prescott S, James K, Hargreave TB et al. (1990) Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144: 1248-1251
45. Prescott S, James K, Hargreave TB et al. (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147: 1636-1642
46. Pryor K, Stricker P, Russell P et al. (1995) Antiproliferative effects of bacillus Calmette-Guerin and interferon α2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 41: 309-316
47. Pryor K, Goddard J, Goldstein D et al. (1995) Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer 71: 801-807
48. Ratliff TL, Shapiro A, Catalona WJ (1986) Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells. Clin Immunol Immunopathol 41: 108-115
49. Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res 47: 1762-1766
50. Ratliff TL, Gillen DP, Catalona WJ (1987) Requirement of a thymus-dependant immune response for BCG- mediated antitumor activity. J Urol 137: 155-158
51. Ratliff TL, Ritchey JK, Yuan JJJ et al. (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150: 1018-1023
52. Riemensberger J, Bohle A, Brandau S (2002) IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 127: 20-26
53. Saint F, Irani J, Salomon L et al. (2001) T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 166: 2142-2147
54. Saint F, Kurth N, Maille P et al. (2003) Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 107: 434-440
55. Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guérin and its correlation with bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res 43: 1611-1615
56. Shin JS, Park JH, Kim JD et al. (1995) Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guerin. Clin Exp Immunol 100: 26-31
57. Soloway MS (1977) Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37: 2918-2929
58. Suttmann H, Lehan N, Bohle A, Brandau S (2003) Stimulation of Neutrophil Granulocytes with Mycobacterium bovis Bacillus Calmette-Guerin Induces Changes in Phenotype and Gene Expression and Inhibits Spontaneous Apoptosis. Infect Immun 71: 4647-4656
59. Suttmann H (2004) Mechanisms of Bacillus Calmette-Guérin-mediated Natural Killer Cell activation. J Urol 172: 1490-1495
60. Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964-1970
61. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K (2005) Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174: 86-91
62. Thalmann GN, Dewald B, Baggiolini M, Studer UE (1997) Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol 158: 1340-1344
63. Thalmann GN (2000) Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164: 2129-2133
64. Thanhauser A (1993) Induction of bacillus-Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 37: 105-111
65. Thanhauser A (1995) The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40: 103-108
66. Watanabe E (2003) Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52: 481-486
67. Weiss GR (2003) Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 26: 343-348
68. Zhao W, Schorey JS, Bong-Mastek M et al. (2000) Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86: 83-88